Synthaverse (SVE.WA) Stock Price

Synthaverse Price

GPW·CLOSED
2.94PLN-0.08 (-2.68 %)
Market closed

Revenue has compounded at 6.2% per year over the past 14 years to 71.76 M PLN. Earnings per share have grown at 1.7% per year over the last 14 years. Synthaverse's net margin stands at 10.5%, broadly stable from 11.1% several years earlier. Analysts set a median price target of 6.63 PLN, implying 125.5% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 11% above its 52-week low.

Synthaverse stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Synthaverse over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Synthaverse stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Synthaverse's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Synthaverse Stock Price History
DateSynthaverse Price
8/7/20262.94 PLN
8/6/20263.02 PLN
8/5/20263.09 PLN
8/4/20263.12 PLN
7/31/20262.79 PLN
7/30/20262.80 PLN
7/29/20262.80 PLN
7/28/20262.74 PLN
7/27/20262.74 PLN
7/24/20262.75 PLN
7/23/20262.79 PLN
7/22/20262.74 PLN
7/21/20262.73 PLN
7/20/20262.73 PLN
7/17/20262.74 PLN
7/16/20262.72 PLN
7/15/20262.73 PLN
7/14/20262.74 PLN
7/13/20262.73 PLN
7/10/20262.75 PLN
7/9/20262.81 PLN
7/8/20262.85 PLN
7/7/20262.89 PLN
7/6/20262.85 PLN
7/3/20262.87 PLN
7/2/20262.86 PLN
7/1/20262.88 PLN
6/30/20262.91 PLN
6/29/20263.00 PLN
6/26/20262.65 PLN
6/25/20262.70 PLN
6/24/20262.68 PLN
6/23/20262.70 PLN
6/22/20262.70 PLN
6/19/20262.69 PLN
6/18/20262.70 PLN
6/17/20262.72 PLN
6/16/20262.74 PLN
6/15/20262.80 PLN
6/12/20262.75 PLN
6/11/20262.72 PLN
6/10/20262.71 PLN
6/9/20262.73 PLN
6/8/20262.69 PLN
6/5/20262.64 PLN
6/3/20262.72 PLN
6/2/20262.73 PLN
6/1/20262.80 PLN
5/29/20262.88 PLN
5/28/20262.91 PLN
5/27/20262.91 PLN
5/26/20262.93 PLN
5/25/20262.92 PLN
5/22/20262.97 PLN
5/21/20263.01 PLN
5/20/20262.99 PLN
5/19/20263.07 PLN
5/18/20263.11 PLN
5/15/20263.08 PLN
5/14/20263.12 PLN
5/13/20263.15 PLN
5/12/20263.16 PLN
5/11/20263.13 PLN
5/8/20263.18 PLN
5/7/20263.15 PLN
5/6/20263.14 PLN
5/5/20263.12 PLN
5/4/20263.05 PLN
4/30/20263.30 PLN
4/29/20263.42 PLN
4/28/20263.43 PLN
4/27/20263.44 PLN
4/24/20263.34 PLN
4/23/20263.40 PLN
4/22/20263.58 PLN
4/21/20263.62 PLN
4/20/20263.64 PLN
4/17/20263.72 PLN
4/16/20263.68 PLN
4/15/20263.71 PLN
4/14/20263.64 PLN
4/13/20263.64 PLN
4/10/20263.63 PLN
4/9/20263.62 PLN
4/8/20263.63 PLN
4/7/20263.62 PLN
4/2/20263.68 PLN
4/1/20263.77 PLN
3/31/20263.72 PLN
3/30/20263.65 PLN
3/27/20263.60 PLN
3/26/20263.62 PLN
3/25/20263.66 PLN
3/24/20263.65 PLN
3/23/20263.68 PLN
3/20/20263.73 PLN
3/19/20263.78 PLN
3/18/20263.87 PLN
3/17/20263.91 PLN
3/16/20263.84 PLN
3/13/20263.72 PLN
3/12/20263.65 PLN
3/11/20263.71 PLN
3/10/20263.69 PLN
3/9/20263.59 PLN
3/6/20263.60 PLN
3/5/20263.67 PLN
3/4/20263.60 PLN
3/3/20263.56 PLN
3/2/20263.65 PLN
2/27/20263.76 PLN
2/26/20263.69 PLN
2/25/20263.66 PLN
2/24/20263.66 PLN
2/23/20263.68 PLN
2/20/20263.70 PLN
2/19/20263.72 PLN
2/18/20263.73 PLN
2/17/20263.74 PLN
2/16/20263.74 PLN
2/13/20263.75 PLN
2/12/20263.78 PLN
2/11/20263.76 PLN
2/10/20263.77 PLN
2/9/20263.75 PLN
2/6/20263.81 PLN
2/5/20263.81 PLN
2/4/20263.83 PLN
2/3/20263.90 PLN
2/2/20263.85 PLN
1/30/20263.91 PLN
1/29/20264.00 PLN
1/28/20264.02 PLN
1/27/20264.02 PLN
1/26/20264.00 PLN
1/23/20263.99 PLN
1/22/20264.00 PLN
1/21/20264.02 PLN
1/20/20264.02 PLN
1/19/20264.07 PLN
1/16/20264.03 PLN
1/15/20264.08 PLN
1/14/20264.09 PLN
1/13/20264.16 PLN
1/12/20264.22 PLN
1/9/20264.19 PLN
1/8/20264.08 PLN
1/7/20264.07 PLN
1/5/20264.03 PLN
1/2/20263.84 PLN
12/30/20253.65 PLN
12/29/20253.62 PLN
12/23/20253.53 PLN
12/22/20253.53 PLN
12/19/20253.58 PLN
12/18/20253.57 PLN
12/17/20253.55 PLN
12/16/20253.70 PLN
12/15/20253.77 PLN
12/12/20253.80 PLN
12/11/20253.83 PLN
12/10/20253.88 PLN
12/9/20253.85 PLN
12/8/20253.86 PLN
12/5/20253.75 PLN
12/4/20253.70 PLN
12/3/20253.76 PLN
12/2/20253.85 PLN
12/1/20253.90 PLN
11/28/20254.04 PLN
11/27/20254.04 PLN
11/26/20253.92 PLN
11/25/20253.93 PLN
11/24/20253.91 PLN
11/21/20253.92 PLN
11/20/20254.02 PLN
11/19/20254.03 PLN
11/18/20254.01 PLN
11/17/20254.01 PLN
11/14/20254.08 PLN
11/13/20254.09 PLN
11/12/20254.10 PLN
11/10/20254.14 PLN
11/7/20254.07 PLN
11/6/20254.09 PLN
11/5/20254.17 PLN
11/4/20254.02 PLN
11/3/20254.05 PLN
10/31/20254.10 PLN
10/30/20254.10 PLN
10/29/20254.14 PLN
10/28/20254.10 PLN
10/27/20254.10 PLN
10/24/20254.19 PLN
10/23/20254.20 PLN
10/22/20254.19 PLN
10/21/20254.18 PLN
10/20/20254.18 PLN
10/17/20254.26 PLN
10/16/20254.26 PLN
10/15/20254.12 PLN
10/14/20254.12 PLN
10/13/20254.15 PLN
10/10/20254.21 PLN
10/9/20254.21 PLN
10/8/20254.23 PLN
10/7/20254.30 PLN
10/6/20254.28 PLN
10/3/20254.23 PLN
10/2/20254.32 PLN
10/1/20254.29 PLN
9/30/20254.38 PLN
9/29/20254.48 PLN
9/26/20254.30 PLN
9/25/20254.30 PLN
9/24/20254.42 PLN
9/23/20254.39 PLN
9/22/20254.40 PLN
9/19/20254.33 PLN
9/18/20254.28 PLN
9/17/20254.39 PLN
9/16/20254.44 PLN
9/15/20254.50 PLN
9/12/20254.49 PLN
9/11/20254.50 PLN
9/10/20254.54 PLN
9/9/20254.62 PLN
9/8/20254.60 PLN
9/5/20254.63 PLN
9/4/20254.70 PLN
9/3/20254.72 PLN
9/2/20254.78 PLN
9/1/20254.78 PLN
8/29/20254.86 PLN
8/28/20254.80 PLN
8/27/20254.88 PLN
8/26/20254.86 PLN
8/25/20254.89 PLN
8/22/20254.89 PLN
8/21/20254.91 PLN
8/20/20254.92 PLN
8/19/20254.91 PLN
8/18/20254.88 PLN
8/14/20255.04 PLN
8/13/20255.00 PLN
8/12/20255.00 PLN
Access this data via the Eulerpool API
Get Free API Key

Synthaverse Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
50.38 M PLN
10.34 M PLN
6.08 M PLN
Jan 1, 2023
58.61 M PLN
9.50 M PLN
4.76 M PLN
Jan 1, 2024
71.76 M PLN
12.65 M PLN
7.55 M PLN
Jan 1, 2025 (e)
41.90 M PLN
1.43 M PLN
15.15 M PLN
Jan 1, 2026 (e)
52.90 M PLN
1.80 M PLN
-18.94 M PLN
Jan 1, 2027 (e)
81.30 M PLN
2.77 M PLN
-3.79 M PLN
Jan 1, 2028 (e)
114.00 M PLN
3.88 M PLN
15.15 M PLN
Jan 1, 2029 (e)
150.40 M PLN
5.12 M PLN
37.89 M PLN

Synthaverse Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 11, 2026, 2:53 AM
 
REVENUEM PLN
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM PLN
EBITM PLN
EBIT MARGIN%
NET INCOMEM PLN
NET INCOME GROWTH%
SHARESM
20152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
42.0036.0031.0032.0039.0040.0041.0050.0058.0071.0041.0052.0081.00114.00150.00155.00
27.27-14.29-13.893.2321.882.562.5021.9516.0022.41-42.2526.8355.7740.7431.583.33
16.6736.1145.1650.0053.8550.0053.6654.0060.3461.9761.9761.9761.9761.9761.9761.97
7.0013.0014.0016.0021.0020.0022.0027.0035.0044.0025.4132.2350.2070.6592.9696.06
-8.00-6.00–-3.006.006.007.0010.009.0012.001.001.002.003.005.005.00
-19.05-16.67–-9.3815.3815.0017.0720.0015.5216.902.441.922.472.633.333.23
-37.00-25.00–-32.002.004.004.006.004.007.0015.00-18.00-3.0015.0037.0053.00
–-32.43––-106.25100.00–50.00-33.3375.00114.29-220.00-83.33-600.00146.6743.24
44.2644.2657.4662.2662.2662.2663.1265.3870.2670.5570.5570.5570.5570.5570.5570.55
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Synthaverse generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Synthaverse retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Synthaverse's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Synthaverse has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Synthaverse's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Synthaverse stock margins

The Synthaverse margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Synthaverse. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Synthaverse.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
51.22 %
16.88 %
11.06 %
Jan 1, 2021
55.09 %
17.35 %
10.33 %
Jan 1, 2022
55.44 %
20.52 %
12.07 %
Jan 1, 2023
60.00 %
16.21 %
8.12 %
Jan 1, 2024
61.67 %
17.63 %
10.52 %
Jan 1, 2025 (e)
61.67 %
3.40 %
36.17 %
Jan 1, 2026 (e)
61.67 %
3.40 %
-35.81 %
Jan 1, 2027 (e)
61.67 %
3.40 %
-4.66 %

Synthaverse Stock Revenue, EBIT, Earnings per Share

The Synthaverse earnings per share therefore indicates how much revenue Synthaverse has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.65 PLN
0.11 PLN
0.07 PLN
Jan 1, 2021
0.65 PLN
0.11 PLN
0.07 PLN
Jan 1, 2022
0.77 PLN
0.16 PLN
0.09 PLN
Jan 1, 2023
0.83 PLN
0.14 PLN
0.07 PLN
Jan 1, 2024
1.02 PLN
0.18 PLN
0.11 PLN
Jan 1, 2025 (e)
0.55 PLN
0.02 PLN
0.20 PLN
Jan 1, 2026 (e)
0.70 PLN
0.03 PLN
-0.25 PLN
Jan 1, 2027 (e)
1.07 PLN
0.04 PLN
-0.05 PLN

Synthaverse business model & stock analysis

Biomed Lublin is a Polish company that has been active in the production of serums and vaccines since 1950. It has grown to become a leading producer of biological substances and medical devices in Eastern Europe. The company was originally a state institution for the development of animal vaccines but was privatized after the political changes in the late 1980s. Since 2002, it has been listed on the Warsaw Stock Exchange and has expanded its focus. Biomed Lublin operates in four main areas: veterinary medicine, human medicine, diagnostics, and laboratory equipment. It has a strong reputation in the veterinary medicine field, offering vaccines and diagnostics for livestock and pets. The company is also involved in human medicine, producing vaccines and diagnostics exclusively in Poland. In the diagnostics field, Biomed Lublin has developed and manufactured a variety of test kits used in medical diagnostics. It also offers laboratory equipment such as microscopes, pipettes, and centrifuges for medical and biological testing in hospitals and laboratories. Overall, Biomed Lublin aims to continue expanding its presence in the biotech industry in Eastern Europe and providing high-quality and effective diagnostic and therapeutic solutions to improve the health of both humans and animals.

Synthaverse SWOT Analysis

Strengths

Biomed Lublin Wytwornia Surowic i Szczepionek SA has several strengths that contribute to its strong position in the market:

  • Strong brand reputation and recognition in the biomedicine industry.
  • Extensive experience and expertise in the development and production of serums and vaccines.
  • High-quality products that meet strict regulatory standards.
  • Well-established distribution channels and partnerships with healthcare organizations.
  • Diverse product portfolio catering to various healthcare needs.

Weaknesses

Despite its strengths, Biomed Lublin Wytwornia Surowic i Szczepionek SA faces certain weaknesses that may hinder its growth:

  • Limited international presence, with most sales generated domestically.
  • Relatively small scale of operations compared to global competitors.
  • Dependency on government funding and regulations for product development and approval.
  • Potential challenges in adapting to rapidly changing industry technologies and standards.
  • Lack of diversification beyond serums and vaccines, limiting revenue streams.

Opportunities

Biomed Lublin Wytwornia Surowic i Szczepionek SA can leverage the following opportunities to expand its market reach:

  • Growing demand for vaccines and serums globally, driven by increasing healthcare awareness.
  • Emerging markets with untapped potential for biomedicine products.
  • Innovation in biotechnology and genetic engineering, opening new possibilities for product development.
  • Collaboration opportunities with research institutions and universities to advance scientific knowledge.
  • Potential partnerships with pharmaceutical companies to enhance manufacturing capabilities.

Threats

Biomed Lublin Wytwornia Surowic i Szczepionek SA should be cautious of the following threats in the competitive market:

  • Intense competition from large global biopharmaceutical companies.
  • Stringent regulatory requirements and compliance costs.
  • Volatility in raw material prices, potentially affecting production costs.
  • Public perception challenges around vaccine safety and effectiveness.
  • Economic downturns and budget cuts in healthcare expenditure.

Synthaverse Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Synthaverse historical P/E ratio, EBIT multiple, and P/S ratio

Synthaverse annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Synthaverse shares outstanding

The number of shares of Synthaverse was 70.55 M in 2025. This indicates how many shares Synthaverse is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
62.26 M Stocks
Jan 1, 2021
63.12 M Stocks
Jan 1, 2022
65.38 M Stocks
Jan 1, 2023
70.26 M Stocks
Jan 1, 2024
70.55 M Stocks
Jan 1, 2025 (e)
70.55 M Stocks
Jan 1, 2026 (e)
70.55 M Stocks
Jan 1, 2027 (e)
70.55 M Stocks

Current Synthaverse forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
80.00 % (4)
Hold
20.00 % (1)
Sell
0.00 % (0)
12M Price Target
6.63
Last Price
2.93
Currency
PLN
12M Return Potential
126.28 %
LTM Return
0 %

Synthaverse shareholder structure

% Name
6.85628%
AgioFunds Towarzystwo Funduszy Inwestycyjnych S.A.
AgioFunds Towarzystwo Funduszy Inwestycyjnych S.A.
6.71008%
Napiora (Wiktor)
Napiora (Wiktor)
6.70899%
Organizacja Polskich Dystrybutorow Farmaceutycznych SA
Organizacja Polskich Dystrybutorow Farmaceutycznych SA
6.68829%
Kucowicz (Dariusz)
Kucowicz (Dariusz)
6.59892%
Unisono Capital Sp z o o SKA
Unisono Capital Sp z o o SKA
6.31527%
Sierocki (Przemyslaw Zbigniew)
Sierocki (Przemyslaw Zbigniew)

Synthaverse Beneficial Ownership Filings (SEC 13D/G)

Free Float
84.8%
Float Shares
-
Shares Outstanding
-

Synthaverse Executives and Management Board

12 members · avg. age 55 · 9 % women

Management

MS

Mieczyslaw Starkowicz

President of the Management Board

–
AC

Mr. Artur Chodkowski

Vice President of the Management Board

–
KK

Ms. Katarzyna Krukowska

Chief Accounting Officer

–

Board of Directors

DK

Mr. Dariusz Kucowicz (53)

Member of the Supervisory Board

232,000.00 PLN
WN

Mr. Wiktor Napiora (62)

Vice Chairman of the Supervisory Board · since 2016

93,000.00 PLN
JB

Mr. Jaroslaw Blaszczak

Chairman of the Supervisory Board · since 2016

68,000.00 PLN
WS

Mr. Waldemar Sierocki (63)

Secretary of the Supervisory Board

1,000.00 PLN
KM

Mr. Konrad Miterski (49)

Independent Member of the Supervisory Board

1,000.00 PLN
PK

Mr. Piotr Kwasniewski

Member of the Supervisory Board

1,000.00 PLN

Frequently asked questions about Synthaverse

The business model of Biomed Lublin Wytwórnia Surowic i Szczepionek SA is focused on the production and distribution of vaccines, serums, and biological products. As a professional stock website, we provide information on the business strategies and operations of Biomed Lublin Wytwórnia Surowic i Szczepionek SA. This Polish company aims to cater to the healthcare industry by delivering high-quality healthcare solutions through the development and manufacturing of vaccines and serums. Biomed Lublin Wytwórnia Surowic i Szczepionek SA's business model revolves around meeting the growing demands for immunization and contributing to public health both nationally and globally.

Biomed Lublin Wytwornia Surowic i Szczepionek SA is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of Biomed Lublin Wytwornia Surowic i Szczepionek SA in the market are other pharmaceutical companies operating in the vaccine and serum production industry. Some notable competitors include GlaxoSmithKline, Pfizer, Sanofi, Merck & Co., and Johnson & Johnson.

Biomed Lublin Wytwornia Surowic i Szczepionek SA is a Polish pharmaceutical company specializing in the development and production of vaccines and serums. With a rich history spanning several decades, Biomed Lublin has emerged as a key player in the healthcare industry. Established in 1950, the company has continuously evolved, leveraging its expertise in immunology and microbiology to create innovative biopharmaceutical solutions. Over the years, Biomed Lublin has contributed significantly to public health, delivering high-quality vaccines to protect against various diseases. Their commitment to research, state-of-the-art facilities, and stringent quality controls has earned Biomed Lublin Wytwornia Surowic i Szczepionek SA a reputation for excellence in the pharmaceutical market.

Biomed Lublin Wytwornia Surowic i Szczepionek SA has achieved several significant milestones. The company has successfully developed and manufactured a range of high-quality vaccines and sera, contributing to the improvement of public health worldwide. It has obtained various regulatory approvals, ensuring the safety and efficacy of its products. Biomed Lublin has also established partnerships with reputable international organizations and pharmaceutical companies, enhancing its global presence in the biopharmaceutical industry. Additionally, the company has invested in research and development, leading to advancements in vaccine production technology and the development of new innovative products. These achievements showcase Biomed Lublin Wytwornia Surowic i Szczepionek SA's dedication to excellence and its commitment to addressing global healthcare challenges.

Biomed Lublin Wytwornia Surowic i Szczepionek SA is primarily present in Poland.

Biomed Lublin Wytwornia Surowic i Szczepionek SA is a renowned company that embodies strong values and a clear corporate philosophy. With its dedication to excellence, innovation, and customer satisfaction, Biomed Lublin strives to provide high-quality vaccines and serum products. The company emphasizes transparency, integrity, and responsible corporate citizenship in all its operations. Biomed Lublin's commitment to research and development ensures the continuous improvement of its products, enabling it to contribute significantly to the healthcare industry. By prioritizing safety, efficacy, and ethical business practices, Biomed Lublin Wytwornia Surowic i Szczepionek SA demonstrates its dedication to improving global health and saving lives.

Analysts currently set an average price target of 6.63 PLN for the Synthaverse stock (median: 6.63 PLN), implying +126.3 % versus the latest price. The consensus is based on 5 analyst ratings.

Synthaverse Analyst Price Targets 2026

5 analysts currently rate the Synthaverse stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Synthaverse to generate revenue of 52.90 M PLN and earnings per share of -0.27 PLN.

Synthaverse Analyst Price Targets 2026

Converted at the current exchange rate, the Synthaverse share trades at 0.68 EUR (2.94 PLN).

The Synthaverse share (SVE.WA) is listed on 5 stock exchanges, including: Frankfurt (6NQ.F), München (6NQ.MU), London (0RKM.L).

Biomed Lublin Wytwornia Surowic i Szczepionek SA is a Polish company specializing in the production of vaccines, serum, and other biological products. The company was established in 1950 and has experienced continuous growth since then. Biomed Lublin is an important member of the Polish biotechnology industry and has established itself as a key supplier of medical products. The company focuses on the production of vaccines, including tetanus, diphtheria, scarlet fever, polio, hepatitis A and B, typhoid, and rabies. Additionally, Biomed Lublin produces serum, antitoxins, and other antibody products that are distributed worldwide. The company's blood products and plasmapheresis products department is also an integral part of its services. Biomed Lublin has multiple state-of-the-art production facilities and the necessary equipment to ensure the quality and effectiveness of its products. It is certified and complies with Good Manufacturing Practices (GMP) standards, ensuring strict quality assurance throughout all phases of product development and manufacturing. Moreover, Biomed Lublin is involved in research and development, collaborating with leading academic institutions in Poland and abroad to create the best possible scientific basis. Exporting its products to countries worldwide is one of the core businesses of Biomed Lublin, with current partner countries including Japan, China, Brazil, Russia, and India. In conclusion, Biomed Lublin is an established biotechnology company with a long history and expertise in the production and distribution of biological products. It has a strong international network and is capable of offering high-quality products at competitive prices.

The expected revenue of Synthaverse is 52.90 M PLN. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Synthaverse is -18.94 M PLN. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Synthaverse is currently -10.95. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Synthaverse stock.

The price-to-sales ratio (P/S) of Synthaverse is currently 3.92. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Synthaverse stock.

The Eulerpool Quality Score for Synthaverse is 5/10.

The ISIN of Synthaverse is PLBMDLB00018. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Synthaverse is A1J10U. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Synthaverse is SVE.WA. The ticker symbol is used to trade Synthaverse shares on the stock exchange.

Synthaverse paid dividends every year for the past 0 years.

Synthaverse is assigned to the 'Health' sector.

The dividends of Synthaverse are distributed in PLN.

All fundamentals and in-depth analysis of Synthaverse

Our stock analysis for Synthaverse stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Synthaverse. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Synthaverse Stock
Synthaverse Revenue→
Synthaverse Stock
Synthaverse Net Income→
Synthaverse Stock
Synthaverse P/E→
Synthaverse Stock
Synthaverse P/S→
Synthaverse Stock
Synthaverse EBIT→
Synthaverse Stock
Synthaverse Dividend→
Synthaverse Stock
Synthaverse Directors Dealings→
Synthaverse Stock
Synthaverse Stocks→
Synthaverse Stock
Synthaverse Market capitalization→
Synthaverse Stock
Synthaverse Debt→
Synthaverse Stock
Synthaverse Liabilities→
Synthaverse Stock
Synthaverse Equity→
Synthaverse Stock
Synthaverse AAQS→
Synthaverse Stock
Synthaverse Employees→
Synthaverse Stock
Synthaverse ROE→
Synthaverse Stock
Synthaverse ROA→
Synthaverse Stock
Synthaverse ROCE→
Synthaverse Stock
Synthaverse News→
Synthaverse Stock
Synthaverse Analyst Price Targets→

Health Stocks

SyntheticMR AB (publ)SyntekaBioSyra HealthSyntaraSyros PharmaceuticalsSynovics PharmaceuticalsSyschem (India)Synmosa BiopharmaSysmexSynlogicT&L CoSyngene InternationalAll Stocks A–Z →